CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL: Leuk Res

A. Majid, T. T. Lin, G. Best, K. Fishlock, S. Hewamana, G. Pratt, D. Yallop, A. G. Buggins, S. Wagner, B. J. Kennedy, F. Miall, R. Hills, S. Devereux, D. G. Oscier, M. J. Dyer, C. Fegan, C. Pepper

Research output: Contribution to journalArticlepeer-review

49 Citations (Scopus)

Abstract

The world of chronic lymphocytic leukemia (CLL) research is awash with prognostic markers. However, very few of the current group play a clearly defined role in the pathology of this disease and even fewer represent a tractable therapeutic target. One such marker that fulfils both of these criteria is the integrin CD49d. This molecule been implicated in the capacity of CLL cells to migrate into lymphoid tissues and there is a CD49d blocking antibody, Natalizumab, currently in clinical trials. Here we carried out the largest multi-centre evaluation of CD49d as a prognostic marker in 652 primary CLL samples. We confirm that CD49d is predictive for time to first treatment (P
Original languageEnglish
Pages (from-to)750-756
Number of pages7
JournalLeukemia Research
Volume35
Issue number6
DOIs
Publication statusPublished - Jun 2011
Externally publishedYes

Fingerprint

Dive into the research topics of 'CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL: Leuk Res'. Together they form a unique fingerprint.

Cite this